Celadon Pharmaceuticals focussed on cannabis-based medicines announced that it has received approval for Good Manufacturing Practice or GMP registration by the UK Medicines and Healthcare products Regulatory Agency or MHRA.

The company's Midlands UK facility has now been registered by the MHRA for the GMP manufacturing of its cannabis Active Pharmaceutical Ingredient or API.

GMP, the globally recognised quality standard required to manufacture pharmaceutical medicines, is an essential requirement for the commercialisation of Celadon's medicinal cannabis product, which will be supplied in oil form as an API.